Nasdaq Profile (CTXR) Trends Green Early On Massive Breaking News (Grab All The Key Details Now)

CTXR is trending green early and requires full focus right now. Here's why. Nasdaq Profile (CTXR) Trends Green Early On Massive Breaking News (Grab All The Key Details Now) May 6th Dear Reader, CTXR is trending green early and requires full focus right now. Here's why. Just a few minutes ago, the company dropped some game-changing news. Check it out: Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally CRANFORD, N.J. , May 6, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has selected Biorasi, LLC ("Biorasi"), a global clinical research organization (CRO), to help expand the Company's Phase 3 Mino-Lok trial to additional sites outside the United States. If approved, Mino-Lok would be the first-and-only antibiotic lock solution FDA-approved to salvage infected central venous catheters (CVCs) causing catheter-related blood stream infections (CRBSIs). "Citius is pleased to collaborate with Biorasi to expand the Mino-Lok trial to include international clinical sites, as originally planned. This complements efforts underway in the U.S. by our lead CRO, Medpace, to drive recruitment. We paused our ex-U.S. strategy as CV19 spread across the globe and hospitals halted non-CVD trials. With the ... pandemic receding, we believe there is now an opportunity to access additional sites and plan to leverage Biorasi's track record of quickly ramping up sites around the world to recruit clinical trial subjects outside the U.S. CRBSIs remain a critical unmet need globally with millions of patients requiring sterile central venous catheters to receive life-saving therapies," stated Leonard Mazur, Chairman and CEO of Citius. "We are committed to continuing to recruit patients until we reach the minimum required trial events, as per FDA guidance and outlined in our trial protocol to achieve statistically significant results. This will enable us to optimize the potential of a successful New Drug Application (NDA) submission. We believe our efforts to establish trial sites outside the U.S., combined with our ongoing initiatives, which have driven a recent increase in study enrollment at our U.S. sites, will assist us in reaching the necessary events to complete the trial by the end of this year," added Mazur. [...] [Read the full article here.]( Could this news act as a potential attention grabbing catalyst today? Remember, as I mentioned previously, this profile has [several oversold leaning technicals]( that could signal a possible bounce/reversal in the near term. With today's early green trend and the news, it may become the spark for CTXR to make a strong vertical move sooner rather than later. Take a second now to review my initial CTXR report below and get it on your radar now. ----- Time's up. Here's what you need to know. In recent weeks, I've been tracking a specific Nasdaq profile quite closely and think it's time to get it on your radar. Oh. And by the way did I mention this was a past champ? On April 19th, 2021, I brought this biopharma profile to your attention only to watch it run from an open that day of $1.99 to a high of $4.56 by June 22nd. Overall, that $2.00+ surge resulted in this breakout idea running approximately 129%. But that was then, this is now. With several potential catalysts including strong analyst coverage with significant price targets, plus key program and milestone updates, and multiple oversold leaning technicals, you literally can't wait another second to get this company pulled up. For Friday, May 6th, there is only one Nasdaq biopharma idea to have on your watch-list: *Citius Pharmaceuticals, Inc. (CTXR)* Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. And right now, this profile has 5 potential catalysts to be fully aware of. They include: No. 1 - Strong Analyst Coverage Including A Pair Of $6.00 Targets No. 2 - Business Highlights And Possible 2022 Catalyst Milestones No. 3 - Topline Results Help Citius Get Closer To Product Commercialization No. 4 - Key Technical Indicators Are Leaning Oversold No. 5 - Major Institutional Positions But more on those in a second... Citius Pharmaceuticals, Inc. (CTXR) Could Be A BioPharma Powerhouse Hiding In Plain Sight Citius Pharmaceuticals is what’s called a “late-stage biopharmaceutical” company, where a highly-experienced management team purchases rights to the most promising new therapies and then either brings them to market or licenses rights to bigger pharma companies like Pfizer or Johnson & Johnson. It should go without saying that “late-stage” development is the most difficult, most expensive part of the process for any new kind of treatment. Because even after years of investment, research and development, some [2 out of 5 drugs]( still fail to secure final FDA approval. But with a “Dream Team” of top industry insiders, Citius is turning the odds in their favor—with two treatments now in Phase 3, and both looking like they will pass. ([Source]( In addition to E-7777, it’s currently advancing three proprietary product candidates in total: - CITI-002 (Halo-Lido), a topical formulation of halobetasol, a corticosteroid, and lidocaine to provide anti-inflammatory and anesthetic symptomatic relief to hemorrhoids victims. It is currently gearing up for a Phase IIb trial. - CITI-101 (Mino-Wrap), a liquefying gel-based wrap containing minocycline and rifampin designed to provide inflammatory tissue protection and prevent infection and biofilm formation in tissue expanders and breast implants post-mastectomy. In December 2020, Citius received a written response and guidance from the USFDA for Mino-Wrap development. Citius expects to file for an IND by the end of this year. - Mino-Lok, an antibiotic lock solution developed as adjunctive therapy for patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloodstream infections (CRBSIs). If approved, Citius believes that Mino-Lok could enter a [$1.5Bn worth market]( prove to be a blockbuster without any immediate competition. ----- And right now, CTXR has 5 potential catalysts to soak in this second. Following along... No. 1 CTXR Potential Catalyst - Strong Analyst Coverage Including A Pair Of $6.00 Targets Analyst coverage on CTXR is at a premium right now. Check it out: ([Source: MarketBeat]( Each brokerage/analyst has given CTXR a target over 100% higher than this Nasdaq past champ's closing valuation as of Thursday. What's even better is HC Wainwright has boosted their target from $4.00 to $6.00. Could CTXR really be as undervalued as these brokerages/analysts suppose? ----- No. 2 CTXR Potential Catalyst - Business Highlights And Possible 2022 Catalyst Milestones Citius Pharmaceuticals, Inc. Provides Business Update, Highlights Upcoming Milestones CRANFORD, N.J., May 3, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today provided a business update for the first quarter ended March 31, 2022 and reported on recent corporate developments and upcoming milestones. Recent Highlights and Upcoming Milestones - Citius anticipates filing a biologics license application (BLA) for I/ONTAK® with the U.S. Food and Drug Administration (FDA) in the second half of 2022; - Topline data from the Phase 3 study of cancer immunotherapy I/ONTAK are consistent with the previously-approved formulation of denileukin diftitox (ONTAK), and there are no new safety signals; - Halo-Lido Phase 2b trial initiated in April 2022 with last patient enrollment anticipated by the end of 2022; - Phase 3 Mino-Lok® trial proceeding without modification as recommended by the independent data monitoring committee (DMC) following all three DMC reviews; - Mino-Lok Phase 3 trial completion anticipated by end of 2022; and, - Pre-clinical development ongoing for Citius' Mino-Wrap and induced mesenchymal stem cell programs. "2022 is a year of important catalysts for Citius as we continue to make progress on multiple fronts. We recently released topline results for I/ONTAK which were consistent with the prior FDA-approved and marketed formulation of denileukin diftitox (ONTAK). In preparation for a planned BLA submission in the second half of 2022, we are marshalling the necessary manufacturing and commercial resources to support the application, and ultimately a successful launch," stated Leonard Mazur, Chairman and CEO of Citius. "Our Mino-Lok program continues to advance in accordance with the recommendations of the independent data monitoring committee, which advised us to continue with the trial as planned, following each of its three data reviews. We remain encouraged by the positive signal conveyed by the DMC guidance to proceed. Coupled with the recent ramp up in patient recruitment following an easing of CV19-related hospital restrictions, we believe our efforts to increase engagement with existing trial sites and to onboard additional sites will continue to drive trial enrollment and enable us to achieve the necessary trial events to support statistically significant results," added Mazur. "In April, we initiated our Phase 2b Halo-Lido trial for the treatment of hemorrhoids. By the end of 2022, we expect to complete trial enrollment. A data readout will follow upon validation and analysis of the information provided in the electronic patient reported outcome tool (ePRO) designed with guidance from the FDA. The results will be used to design the Phase 3 trial. As this product would ultimately be marketed directly to consumers, rather than to targeted physician and hospital groups like our other pipeline candidates, we will evaluate alternatives to optimize the value of this asset as we advance the program. Citius considers all strategic alternatives to maximize the value of our portfolio, individually and collectively, on an ongoing basis. We believe we remain well capitalized to advance our programs through multiple catalysts this year, and we plan to continue building long-term value in the business by focusing on execution," concluded Mr. Mazur. 2022 Achieved and Anticipated Catalysts - Report Topline results of I/ONTAK Phase 3 trial (April 2022) - Initiate Halo-Lido Phase 2b trial (April 2022) - Submit I/ONTAK BLA application (2H 2022) - Complete enrollment in Mino-Lok Phase 3 trial (end of 2022) - Complete enrollment in Halo-Lido Phase 2b trial (end of 2022) [Read the full article here.]( ----- No. 3 CTXR Potential Catalyst - Topline Results Help Citius Get Closer To Product Commercialization Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Support of BLA Submission CRANFORD, N.J., April 6, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products in oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies, today reported topline results from the pivotal Phase 3 trial of I/ONTAK (E7777), an engineered IL-2-diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL). The topline results for I/ONTAK (denileukin diftitox), a purified and more bioactive formulation of previously marketed ONTAK®, were consistent with the prior formulation. Moreover, no new safety signals were identified. Based on this data, Citius anticipates filing a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA) in the second half of 2022. "We are encouraged by the results of the study, which we believe are clinically meaningful, and are hopeful that I/ONTAK will be an important treatment option for patients with persistent or recurrent CTCL. There is no single standard of care for this orphan disease. We believe the full body of data from this and prior studies will support a successful reintroduction of denileukin diftitox to the market. We are eager to move forward with a BLA submission for the treatment of CTCL later this year. This important milestone brings Citius one step closer to launching its first commercial product next year, if approved by the FDA," stated Myron Holubiak, Chief Executive Officer of Citius. "The topline results demonstrated anti-tumor activity in the treatment of persistent or recurrent CTCL, an incurable disease. Based on the topline data, I/ONTAK provided disease control without cumulative toxicity. I/ONTAK has a unique dual mechanism of action that exerts both direct tumor cell killing and transient elimination of immunosuppressive Tregs within the tumor microenvironment. The topline data further demonstrate that I/ONTAK has an average time to response within one to two cycles of treatment in patients that have failed multiple prior therapies. If approved, we believe this biologic with its observed efficacy and safety data, and which is already approved for CTCL and peripheral T-cell lymphoma (PTCL) patients in Japan, would arm oncologists in the U.S. with an important additional treatment option for this devastating orphan disease," added Dr. Myron Czuczman, Chief Medical Officer of Citius. [...] [Read the full article here.]( ----- No. 4 CTXR Potential Catalyst - Key Technical Indicators Are Leaning Oversold As of close on Thursday, Barchart was reporting this profile to have several oversold leaning technicals. These technicals could be signaling a healthy reversal in the near term. Here's the definition of a "reversal" from [Investopedia]( "A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart." Now, here are [some key technicals]( of close Thursday) that could signal CTXR to be leaning oversold and on the verge of a potential reversal. - 9-Day Relative Strength Index: 29.68% - 14-Day Relative Strength Index: 30.99% When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued. - 14-Day Raw Stochastic: 10.96% - 14-Day Williams %R: 89.04% As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued. Keep an eye on these technicals closely. ----- No. 5 CTXR Potential Catalyst - Major Institutional Positions Over at [WhaleWisdom]( you can see which asset management companies and hedge funds think CTXR could be in for a bright future. Here's a quick breakdown: (1.) Allspring Global Investments Holdings is an assets management fund who recently jumped on the CTXR train when they added over 500k shares (reported 1/28/22). (2.) American in-vestment ad-visor, Vanguard Group has a total position of approximately 6.17Mn overall shares after adding roughly 398k more (reported on 2/14/22). (3.) In-vestment management company, BlackRock Inc., currently owns 5%+ of CTXR and a total of approx. 8.12Mn shares (reported on 2/23/22). Don't think twice about this. This is huge news and only the tip of the iceberg. Just take a look at WhaleWisdom's site and you'll see how many different institutions are taking positions in CTXR. Could it be that these institutions see a big future for this Nasdaq profile? ----- CTXR Recap - 5 Potential Catalysts For This Nasdaq Past Champ No. 1 - Strong Analyst Coverage Including A Pair Of $6.00 Targets No. 2 - Business Highlights And Possible 2022 Catalyst Milestones No. 3 - Topline Results Help Citius Get Closer To Product Commercialization No. 4 - Key Technical Indicators Are Leaning Oversold No. 5 - Major Institutional Positions ----- Coverage is officially reinitiated on CTXR. When you have time later, do this: Get CTXR on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer I am not a lic-ensed fina-ncial adviser. All potential percentage gains are based on from the low to the high of day. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. An owner of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. A member of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stock street wire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 7/26/19 and ending on 7/29/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid five thousand USD via bank check. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor. Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews was hired for a period beginning on 7/26/19 and ending on 7/29/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI has been hired for a period beginning on 9/3/19 and ending on 9/4/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid five thousand USD via ACH. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor. Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a period beginning on 9/3/19 and ending on 9/4/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between Fierce Investor (FI) and StockNewsWire LLC, FI has been hired for a period beginning on 12/18/19 and ending on 12/19/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid five thousand USD via ACH. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor. Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a period beginning on 12/18/19 and ending on 12/19/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI has been hired for a one day period on 2/4/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid five thousand USD via ACH. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor. Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 2/4/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor. Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 3/11/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI has been hired for a period beginning on 4/2/20 and ending on 4/3/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid five thousand USD via ACH. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor. Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a period beginning on 4/2/20 and ending on 4/3/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty-five thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI has been hired for a one day period on 4/28/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid seven thousand five hundred USD via ACH. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in Fierce Investor. Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 4/28/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor. Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 5/13/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI has been hired for a two day period beginning on 6/2/20 and ending on 6/3/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid three thousand five hundred USD via ACH. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in Fierce Investor. Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a two day period beginning on 6/2/20 and ending on 6/3/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI has been hired for a two day period beginning on 7/7/20 and ending on 7/8/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid five thousand USD via ACH. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a two day period beginning on 7/7/20 and ending on 7/8/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in Fierce Investor (FI). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a two day period beginning on 8/4/20 and ending on 8/5/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid ten thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI has been hired for a two day period beginning on 9/17/20 and ending on 9/18/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid five thousand USD via ACH. We own zero shares of (CTXR). To date, we have been compensated forty-six thousand USD via bank check and ACH to disseminate information about (CTXR). An owner of StockNewsWire LLC owns an interest in Fierce Investor (FI). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a two day period beginning on 9/17/20 and ending on 9/18/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a one day period beginning on 10/6/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid ten thousand USD via bank wire transfer. We own zero shares of (CTXR).   An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for an additional one day period beginning on 10/8/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid two thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI has been hired for a one day period beginning on 12/8/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid fifteen thousand USD via ACH. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for an additional one day period beginning on 12/8/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid sixty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockStreetWire (SSW) and StockNewsWire LLC, SSW has been hired for a period beginning on 2/16/21 and ending on 2/17/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid seventeen thousand five hundred USD via ACH. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI) and StockStreetWire (SSW). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 2/16/21 and ending on 2/17/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI has been hired for a period beginning on 4/29/21 and ending on 4/30/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid twenty thousand USD via ACH. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 4/29/21 and ending on 4/30/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid ninety-five thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between NasdaqWireNews (NWN) and StockNewsWire LLC, NWN has been hired for a period beginning on 5/18/21 and ending on 5/19/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid five thousand USD via ACH. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI) and NasdaqWireNews (NWN). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 5/18/21 and ending on 5/19/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid five thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between NasdaqWireNews (NWN) and StockNewsWire LLC, NWN has been hired for a period beginning on 6/8/21 and ending on 6/9/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid seven thousand five hundred USD via ACH. We own zero shares of (CTXR).  An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI) and NasdaqWireNews (NWN). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 6/8/21 and ending on 6/9/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI has been hired for a period beginning on 6/16/21 and ending on 6/17/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid twenty thousand USD via ACH. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 6/16/21 and ending on 6/17/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid ninety-five thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI has been hired for a period beginning on 7/8/21 and ending on 7/9/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid two thousand five hundred USD via ACH. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 7/8/21 and ending on 7/9/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI has been hired for a period beginning on 9/7/21 and ending on 9/8/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid fifteen thousand USD via ACH. We own zero shares of (CTXR). To date we have now been compensated a total of one hundred and thirty-eight thousand five hundred USD via bank check and ACH to disseminate information about (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 9/7/21 and ending on 9/8/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. StockNewsWire LLC was paid sixty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI has been hired for a period beginning on 12/6/21 and ending on 12/7/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid five thousand USD via ACH. We own zero shares of (CTXR). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 12/6/21 and ending on 12/7/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. StockNewsWire LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a one day period on 5/6/22 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid fifteen thousand USD via ACH. We own zero shares of (CTXR). To date we have been compensated a total of one hundred and fifty-eight thousand five hundred USD via ACH to disseminate information about (CTXR). This fifteen thousand USD may be used for future marketing and advertising on this company or other companies on an ongoing basis. All companies will be disclosed. An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a one day period on 5/6/22 to publicly disseminate information about (CTXR) via Website, Email and SMS. StockNewsWire LLC was paid eighty-two thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (CTXR). To date we have now been compensated a total of six hundred and thirty thousand five hundred USD via bank wire transfer to disseminate information about (CTXR). This eighty-two thousand five hundred USD may be used for future marketing and advertising on this company or other companies on an ongoing basis. All companies will be disclosed. Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 3/15/22 and ending on 3/16/22 to publicly disseminate information about (USAU) via Website, Email and SMS. We were paid fifteen thousand USD via ACH. We own zero shares of (USAU). To date we have been compensated a total of fifty-five thousand USD via ACH to disseminate information about (USAU). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 3/15/22 and ending on 3/16/22 to publicly disseminate information about (USAU) via Website, Email and SMS. StockNewsWire LLC was paid eighty-two thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (USAU). To date we have been compensated a total of two hundred eighty-nine thousand five hundred USD via bank wire transfer to disseminate information about (USAU). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 2/23/22 and ending on 2/24/22 to publicly disseminate information about (BTCY) via Website, Email and SMS. We were paid fifteen thousand USD via ACH. We own zero shares of (BTCY). To date we have been compensated a total of forty thousand USD via ACH to disseminate information about (BTCY). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 2/23/22 and ending on 2/24/22 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid eighty-two thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). To date we have been compensated a total of two hundred thousand USD via bank wire transfer to disseminate information about (BTCY). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 1/20/22 and ending on 1/21/22 to publicly disseminate information about (IMMX) via Website, Email and SMS. We were paid fifteen thousand USD via ACH. We own zero shares of (IMMX). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 1/20/22 and ending on 1/21/22 to publicly disseminate information about (IMMX) via Website, Email and SMS. StockNewsWire LLC was paid eighty-two thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (IMMX). Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net